Compare Ascendis Pharma A/S (ASND) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Under Armour Inc Class A — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Under Armour Inc Class A trades at $6.75 (market cap $2.86B). The key difference: Ascendis Pharma A/S is far larger — about 6.2× Under Armour Inc Class A's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ASND | UA | |
|---|---|---|
Market Cap | $17.74B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $7.88 |
52-Week Low | $163.32 | $3.96 |
Enterprise Value | $18.11B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Under Armour (UA) trades at $6.61, up 2.48% with a bullish technical signal from moving averages. The company reported mixed Q1 2026 results with an EPS miss but maintains a 40.3% analyst buy rating. Recent financials show revenue of $5.16B for 2025 with negative net income of -$201.27M, though gross margins remain healthy at 45.48%. The Dodge collaboration and institutional buying by Prem Watsa provide positive catalysts amid ongoing business restructuring.
The outlook remains challenging with declining revenue projections and negative profitability metrics, but current valuation at 0.57 P/S offers potential for turnaround investors. Key risks include sustained revenue declines, competitive pressures, and negative cash flow trends. Institutional sentiment appears cautiously optimistic despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
